Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study.
Ridolfi L, De Rosa F, Petracci E, Tanda ET, Marra E, Pigozzo J, Marconcini R, Guida M, Cappellini GCA, Gallizzi G, Occelli M, Pala L, Gambale E, Bersanelli M, Galdo G, Cortellini A, Morgese F, Zoratto F, Stucci LS, Strippoli S, Guidoboni M; Italian Melanoma Intergroup (IMI). Ridolfi L, et al. J Geriatr Oncol. 2020 Apr;11(3):515-522. doi: 10.1016/j.jgo.2019.12.012. Epub 2020 Jan 9. J Geriatr Oncol. 2020. PMID: 31928943
Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Ridolfi L, Fiorentini G, Guida M, Michiara M, Freschi A, Aitini E, Ballardini M, Bichisao E, Ridolfi R; Italian Melanoma Intergroup. Ridolfi L, et al. Among authors: ridolfi r. Melanoma Res. 2009 Apr;19(2):100-5. doi: 10.1097/CMR.0b013e328328f7ec. Melanoma Res. 2009. PMID: 19262411 Clinical Trial.
Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis.
Ridolfi L, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Scarpi E, Guidoboni M, Migliori G, Sanna S, Tauceri F, Verdecchia GM, Riccobon A, Valmorri L, Ridolfi R. Ridolfi L, et al. Among authors: ridolfi r. Clin Dev Immunol. 2010;2010:504979. doi: 10.1155/2010/504979. Epub 2010 Sep 27. Clin Dev Immunol. 2010. PMID: 20936106 Free PMC article. Clinical Trial.
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Chiarion-Sileni V, Guida M, Ridolfi L, Romanini A, Del Bianco P, Pigozzo J, Brugnara S, Colucci G, Ridolfi R, De Salvo GL; Italian Melanoma Intergroup (IMI). Chiarion-Sileni V, et al. Among authors: ridolfi r, ridolfi l. Br J Cancer. 2011 Jun 7;104(12):1816-21. doi: 10.1038/bjc.2011.178. Epub 2011 May 24. Br J Cancer. 2011. PMID: 21610711 Free PMC article. Clinical Trial.
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.
Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, Boitano M, Calabrò L, Rossi CD, Giacomo AM, Ferrucci PF, Ridolfi L, Altomonte M, Miracco C, Balestrazzi A, Maio M. Danielli R, et al. Among authors: ridolfi r, ridolfi l. Cancer Immunol Immunother. 2012 Jan;61(1):41-8. doi: 10.1007/s00262-011-1089-0. Epub 2011 Aug 11. Cancer Immunol Immunother. 2012. PMID: 21833591 Free PMC article. Clinical Trial.
Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome.
Ridolfi L, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Brolli C, Selva M, Scarpi E, Valmorri L, Nicoletti SV, Guidoboni M, Riccobon A, Ridolfi R. Ridolfi L, et al. Among authors: ridolfi r. Melanoma Res. 2011 Dec;21(6):524-9. doi: 10.1097/CMR.0b013e32834b58fa. Melanoma Res. 2011. PMID: 21909041
Ipilimumab in advanced melanoma: reports of long-lasting responses.
Farolfi A, Ridolfi L, Guidoboni M, Nicoletti SV, Piciucchi S, Valmorri L, Costantini M, Scarpi E, Amadori D, Ridolfi R. Farolfi A, et al. Among authors: ridolfi r, ridolfi l. Melanoma Res. 2012 Jun;22(3):263-70. doi: 10.1097/CMR.0b013e328353e65c. Melanoma Res. 2012. PMID: 22516968
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
Ridolfi L, Petrini M, Granato AM, Gentilcore G, Simeone E, Ascierto PA, Pancisi E, Ancarani V, Fiammenghi L, Guidoboni M, de Rosa F, Valmorri L, Scarpi E, Nicoletti SV, Baravelli S, Riccobon A, Ridolfi R. Ridolfi L, et al. Among authors: ridolfi r. J Transl Med. 2013 May 31;11:135. doi: 10.1186/1479-5876-11-135. J Transl Med. 2013. PMID: 23725550 Free PMC article.
194 results